Managing Drug Supply: Trends, Challenges, and Strategies

Given the current geopolitical challenges, ensuring the availability, efficacy, and quality of drugs has become a priority for the Russian government’s healthcare policy. Creating a sustainable and independent pharmaceutical system requires coordinated action across all sectors – from R&D and production to control and logistics. Key challenges include the development of innovative drugs and the implementation of import substitution policies, which require collaboration between research institutes, manufacturing companies, and the government. Particular attention is being paid to the development of a raw material base, since access to substances that meet the requirements of good manufacturing practices impacts pharmaceutical sovereignty and national security. In terms of quality control, multi-level monitoring is being introduced at all stages of the drug life cycle – from development to post-marketing surveillance. Optimizing regulatory procedures, digitalizing quality control, and creating rapid risk response mechanisms are turning into key objectives. What measures are being taken to enhance the industry’s investment appeal? How is the issue of quality assurance and the validation of raw material supply chains being addressed in the current geopolitical situation? What mechanisms can help to synchronize the development and registration of new products with the production of the required domestic substances or materials in order to avoid supply chain disruptions? What mechanisms are already in place to promptly respond to and remove defective products from circulation at all stages of the supply chain?